Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia
- PMID: 24712661
- DOI: 10.1021/jm4019299
Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia
Abstract
The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor β (THR-β) in the liver, while adverse effects, including cardiac effects, are mediated by thyroid hormone receptor α (THR-α). A pyridazinone series has been identified that is significantly more THR-β selective than earlier analogues. Optimization of this series by the addition of a cyanoazauracil substituent improved both the potency and selectivity and led to MGL-3196 (53), which is 28-fold selective for THR-β over THR-α in a functional assay. Compound 53 showed outstanding safety in a rat heart model and was efficacious in a preclinical model at doses that showed no impact on the central thyroid axis. In reported studies in healthy volunteers, 53 exhibited an excellent safety profile and decreased LDL cholesterol (LDL-C) and triglycerides (TG) at once daily oral doses of 50 mg or higher given for 2 weeks.
Similar articles
-
Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.Atherosclerosis. 2013 Oct;230(2):373-80. doi: 10.1016/j.atherosclerosis.2013.07.056. Epub 2013 Aug 21. Atherosclerosis. 2013. PMID: 24075770 Clinical Trial.
-
Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH).PLoS One. 2020 Dec 11;15(12):e0240338. doi: 10.1371/journal.pone.0240338. eCollection 2020. PLoS One. 2020. PMID: 33306682 Free PMC article.
-
Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-toxicity analysis.Eur J Med Chem. 2020 Feb 15;188:112006. doi: 10.1016/j.ejmech.2019.112006. Epub 2019 Dec 23. Eur J Med Chem. 2020. PMID: 31931337
-
Thyroid Hormone Analogues: An Update.Thyroid. 2020 Aug;30(8):1099-1105. doi: 10.1089/thy.2020.0071. Epub 2020 Apr 7. Thyroid. 2020. PMID: 32098589 Free PMC article. Review.
-
Thyroid Hormone Mimetics: the Past, Current Status and Future Challenges.Curr Atheroscler Rep. 2016 Mar;18(3):14. doi: 10.1007/s11883-016-0564-7. Curr Atheroscler Rep. 2016. PMID: 26886134 Free PMC article. Review.
Cited by
-
Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis.Diabetes. 2018 Dec;67(12):2485-2493. doi: 10.2337/dbi18-0024. Diabetes. 2018. PMID: 30459251 Free PMC article. Review.
-
Understanding the Relationship between Nonalcoholic Fatty Liver Disease and Thyroid Disease.Int J Mol Sci. 2023 Sep 27;24(19):14605. doi: 10.3390/ijms241914605. Int J Mol Sci. 2023. PMID: 37834051 Free PMC article. Review.
-
Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease.Clin Mol Hepatol. 2021 Apr;27(2):221-235. doi: 10.3350/cmh.2020.0239. Epub 2020 Dec 3. Clin Mol Hepatol. 2021. PMID: 33317243 Free PMC article. Review.
-
Current treatment paradigms and emerging therapies for NAFLD/NASH.Front Biosci (Landmark Ed). 2021 Jan 1;26(2):206-237. doi: 10.2741/4892. Front Biosci (Landmark Ed). 2021. PMID: 33049668 Free PMC article. Review.
-
Main Factors Involved in Thyroid Hormone Action.Molecules. 2021 Dec 3;26(23):7337. doi: 10.3390/molecules26237337. Molecules. 2021. PMID: 34885918 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Miscellaneous
